Therapeutic Range for Amitriptyline
The therapeutic range for amitriptyline is 80-200 ng/mL when measured as the combined plasma concentration of amitriptyline plus its active metabolite nortriptyline, with this being a Level 1 "strongly recommended" indication for therapeutic drug monitoring (TDM). 1
Evidence Quality and Recommendation Strength
The AGNP-TDM Expert Group Consensus Guidelines provide the highest quality evidence for amitriptyline monitoring, designating it as Level 1: Strongly Recommended 1. This is the highest recommendation level, indicating:
- Established therapeutic range with controlled clinical trials demonstrating TDM benefit
- Clear evidence of toxic effects at supratherapeutic concentrations
- Highest probability of response within the therapeutic window
- Response rates similar to placebo at subtherapeutic levels
- Increasing risk of adverse effects above therapeutic concentrations
Key Measurement Details
Critical point: The 80-200 ng/mL range represents the combined concentration of amitriptyline plus nortriptyline (its active metabolite), not amitriptyline alone 1. This is essential because:
- Both compounds contribute to therapeutic effect
- Nortriptyline itself has a narrower therapeutic window (70-170 ng/mL when used alone) 1
- Individual metabolism varies significantly between patients
Alternative Therapeutic Windows in Literature
While the 80-200 ng/mL range has the strongest evidence base, other studies have reported slightly different ranges:
- 93-140 ng/mL: One analysis found this narrower window with 50% response rate inside versus 30% outside, though with lower sensitivity (37%) and specificity (80%) 2
- 150-350 ng/mL: Some studies suggest this broader range as safe and therapeutically effective 3
- 68-185 ng/mL: Another study identified this range for therapeutic effectiveness 4
However, the 80-200 ng/mL consensus range should be prioritized as it represents expert consensus based on multiple studies and has the highest level of recommendation 1.
Clinical Application
When to Measure Levels
TDM is particularly valuable in these situations 1:
- Lack of clinical response despite adequate dosing
- Suspected noncompliance
- Adverse effects at standard doses
- Drug interactions (especially with CYP2D6 or CYP2C19 inhibitors)
- Elderly patients (>65 years) who have higher plasma levels for given doses 5
- Patients with hepatic or renal insufficiency
- Genetic polymorphisms affecting metabolism (CYP2D6 poor or ultra-rapid metabolizers)
Dosing Context
At standard doses of 150 mg/day, typical steady-state concentrations show wide variability 1:
- Amitriptyline: 76-122 ng/mL (mean values from different studies)
- Nortriptyline: 71-85 ng/mL (mean values)
- Combined: typically 150-200 ng/mL range
The FDA label notes that plasma levels are difficult to correlate directly with therapeutic effect due to wide variation in absorption and distribution, but levels are useful for identifying toxicity or non-compliance 5.
Safety Considerations
Above 200 ng/mL (combined): Risk of adverse effects increases significantly, including:
- Anticholinergic effects (dry mouth, constipation, urinary retention)
- Cardiac conduction abnormalities
- EEG abnormalities (particularly above 250 ng/mL) 6
- CNS toxicity
Upper safety limit: Some evidence suggests 350 ng/mL as the upper limit where serious complications become more likely 3, though the therapeutic range consensus stops at 200 ng/mL to maintain optimal benefit-risk ratio.
Common Pitfalls
- Measuring only amitriptyline: Always measure both amitriptyline and nortriptyline together
- Timing of blood draw: Obtain trough levels (just before next dose) at steady state (typically 5-7 days after dose changes)
- Elderly patients: Expect higher plasma levels due to decreased hepatic metabolism and increased intestinal transit time 5
- Drug interactions: CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) can dramatically increase levels 7